Phase 3 Epilepsy trials in Romania

Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.

• A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy NCT05109234·Phase 3·Completed·UCB Biopharma SRL·Started 2022
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy NCT04666610·Phase 3·Completed·UCB Biopharma SRL·Started 2021
• A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment NCT04627285·Phase 3·Completed·UCB Biopharma SRL·Started 2020
• A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy NCT03739840·Phase 3·Terminated·UCB Biopharma SRL·Started 2019
• A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994 NCT02582866·Phase 3·Completed·UCB Biopharma S.P.R.L.·Started 2016
• Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures NCT02408549·Phase 3·Completed·UCB BIOSCIENCES, Inc.·Started 2015
• Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures NCT02477839·Phase 3·Completed·UCB BIOSCIENCES, Inc.·Started 2015
• A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications NCT02408523·Phase 3·Completed·UCB BIOSCIENCES, Inc.·Started 2015
• A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures. NCT02072824·Phase 3·Completed·Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·Started 2014
• A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures NCT01964560·Phase 3·Completed·UCB BIOSCIENCES, Inc.·Started 2014
• Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures NCT01921205·Phase 3·Completed·UCB Pharma·Started 2013
• A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures. NCT01747915·Phase 3·Completed·Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·Started 2013
• Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older NCT01465997·Phase 3·Completed·UCB BIOSCIENCES GmbH·Started 2012
• A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures NCT01463306·Phase 3·Completed·Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·Started 2012
• eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam NCT01484977·Phase 3·Completed·UCB Pharma·Started 2011
• A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years NCT01389596·Phase 3·Completed·Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·Started 2011
• Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older NCT01243177·Phase 3·Completed·UCB BIOSCIENCES GmbH·Started 2011
• Once-A-Day Pregabalin For Partial Seizures NCT01262677·Phase 3·Completed·Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·Started 2011
• Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients NCT01422720·Phase 3·Completed·Bial - Portela C S.A.·Started 2010
• Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures NCT00735397·Phase 3·Completed·Eisai Inc.·Started 2008
• Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures NCT00692003·Phase 3·Terminated·Eisai Limited·Started 2008
• Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy NCT00693017·Phase 3·Terminated·Eisai Limited·Started 2008
• Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children NCT00988156·Phase 3·Completed·Bial - Portela C S.A.·Started 2007
• Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy NCT00280059·Phase 3·Completed·Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·Started 2006
• Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy NCT00175903·Phase 3·Completed·UCB Pharma·Started 2005